BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lamb LS, Sim HW, McCormack AI. Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?". Cancers (Basel) 2020;12:E308. [PMID: 32012988 DOI: 10.3390/cancers12020308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Nie D, Fang Q, Li B, Cheng J, Li C, Gui S, Zhang Y, Zhao P. Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World J Surg Oncol 2021;19:162. [PMID: 34090476 DOI: 10.1186/s12957-021-02272-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhou J, Hu Y, Zhu W, Nie C, Zhao W, Faje AT, Labelle KE, Swearingen B, Lee H, Hedley-whyte ET, Zhang X, Jones PS, Miller KK, Klibanski A, Zhou Y, Soberman RJ. Sprouting Angiogenesis in Human Pituitary Adenomas. Front Oncol 2022;12:875219. [DOI: 10.3389/fonc.2022.875219] [Reference Citation Analysis]
3 Fedele M. Pituitary Tumors: New Insights into Molecular Features, Diagnosis and Therapeutic Targeting. Cancers (Basel) 2021;13:1697. [PMID: 33916675 DOI: 10.3390/cancers13071697] [Reference Citation Analysis]
4 Liu PY, Chang WT, Wu SN. Characterization of the Synergistic Inhibition of IK(erg) and IK(DR) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor. Int J Mol Sci 2020;21:E8078. [PMID: 33138174 DOI: 10.3390/ijms21218078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lin AL, Donoghue MTA, Wardlaw SL, Yang TJ, Bodei L, Tabar V, Geer EB. Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. J Clin Endocrinol Metab 2020;105:dgaa649. [PMID: 32930787 DOI: 10.1210/clinem/dgaa649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Yamamoto M, Nakao T, Ogawa W, Fukuoka H. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. Front Endocrinol (Lausanne) 2021;12:650791. [PMID: 34220707 DOI: 10.3389/fendo.2021.650791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lamb LS, Sim HW, McCormack AI. Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol (Lausanne) 2020;11:576027. [PMID: 33312158 DOI: 10.3389/fendo.2020.576027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Postma MR, Kuijlen JMA, Korsten AGW, Westerlaan HE, van den Bergh ACM, Nuver J, den Dunnen WFA, van den Berg G. An aggressive poorly differentiated plurihormonal Pit-1-positive adenoma. Endocrinol Diabetes Metab Case Rep 2021;2021:EDM200166. [PMID: 34673544 DOI: 10.1530/EDM-20-0166] [Reference Citation Analysis]
9 Das L, Rai A, Salunke P, Ahuja CK, Sood A, Radotra BD, Sood R, Korbonits M, Dutta P. Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes. Journal of the Endocrine Society 2022;6:bvab190. [DOI: 10.1210/jendso/bvab190] [Reference Citation Analysis]
10 Nie D, Xue Y, Fang Q, Cheng J, Li B, Wang D, Li C, Gui S, Zhang Y, Zhao P. Immune Checkpoints: Therapeutic Targets for Pituitary Tumors. Dis Markers 2021;2021:5300381. [PMID: 34447484 DOI: 10.1155/2021/5300381] [Reference Citation Analysis]
11 Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne) 2020;11:608422. [PMID: 33362722 DOI: 10.3389/fendo.2020.608422] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]